Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market (2026 - 2036)

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Forecast and Outlook By Fact.MR

In 2025, the rye bran beta-glucan as cholesterol-lowering food ingredient market was valued at USD 0.5 billion. Based on Fact.MR analysis, demand for rye bran beta-glucan as a cholesterol-lowering food ingredient is estimated to grow to USD 0.7 billion in 2026 and USD 1.3 billion by 2036. FACT.MR projects a CAGR of 6.0% during the forecast period.

Summary of Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market

• Market Definition
  • Market covers cereal-based and yeast-derived beta-glucan concentrates used as cholesterol-lowering ingredients.
• Demand Drivers
  • EFSA-approved claims are driving adoption in European food products.
  • China nutraceutical growth is increasing beta-glucan demand.
  • Japan ageing population is supporting FOSHU-based product demand.
• Key Segments Analyzed
  • By Source: Cereal-based leads with 46% share in 2026 due to regulatory approval and supply scale.
  • By Type: Soluble leads with 63% share due to functional cholesterol-lowering properties.
  • By Application: Food & beverages lead with 45% share driven by product fortification demand.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha highlights the importance of purity, viscosity data, and regulatory documentation. Suppliers with validated claims will capture premium market share.
• Strategic Implications
  • Invest in high-purity extraction and regulatory dossier development.
  • Use traceability and standardisation to differentiate from commodity products.
  • Expand into pharmaceutical and FOSHU-regulated applications.
• Methodology
  • Market sizing based on production volumes and pricing benchmarks.
  • Supported by EFSA, FDA, FOSHU, and FSSAI data.
  • Forecasts include regulatory timelines and procurement trends.

The market is expected to generate around USD 0.6 billion in incremental revenue over the forecast period. Growth is driven by clean-label reformulation in bakery and beverage segments. Dietary supplement demand is also expanding. Pharmaceutical-grade applications are emerging as an additional driver. However, high extraction costs for purified beta-glucan remain a constraint. Variability in rye harvest yields also impacts supply and pricing stability.

China leads with 8.4% CAGR through 2036. Growth is driven by functional food demand and nutraceutical expansion. India follows at 8.0%, supported by rising health awareness and product reformulation. Japan grows at 7.2% with strong demand for premium heart-healthy ingredients. Germany records 6.8%, driven by clean-label adoption and rye consumption. The United States grows at 6.0%, supported by use in beverages and protein bars but limited by cost competition.

Segmental Analysis

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Analysis by Source

Based on FACT.MR, cereal-based beta-glucan holds around 46% share in 2026. It leads due to EFSA and FDA-approved health claims. It is cost-effective and widely available from oat and rye bran. It also fits clean-label functional food formulations.

• Tate & Lyle Acquisition of CP Kelco: The company completed a USD 1.8 billion acquisition in 2024. This expands its nature-based ingredient portfolio. It strengthens supply of health-claim compliant ingredients globally. [2]
• Lesaffre Acquisition of Biorigin: Lesaffre acquired a majority stake in 2024. This expands yeast-derived beta-glucan production. It strengthens its position in food and nutraceutical markets. [3]
• Cereal Beta-Glucan Trend: Cereal sources accounted for over 42% of market revenue in 2024. Established supply chains support consistent availability. FDA health claim validation supports commercial adoption. [4]

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Analysis by Type

Soluble beta-glucan holds around 63% share in 2026. It leads due to its proven cholesterol-lowering mechanism. It is the only format approved for on-pack health claims. This makes it critical for regulated markets.

• Layn Natural Ingredients Galacan Launch: The company introduced a soluble beta-glucan product in 2025. It offers improved solubility and bioavailability. It is targeting functional food and supplement applications. [5]
• EFSA Paramylon Approval: EFSA approved paramylon as a novel ingredient in 2024. This expands beta-glucan sourcing pathways. It also supports innovation in soluble formats. [6]
• Soluble Format Trend: Food and beverages led soluble beta-glucan demand in 2024. Supplement demand is growing at a faster rate. This reflects rising adoption in cholesterol management products.

Drivers, Restraints, and Opportunities

Fact.MR notes the market has shifted to a precision-nutrition phase. Growth is driven by EFSA and FDA-backed health claims. Demand is expanding beyond Europe into Asia Pacific. Ageing populations and nutraceutical growth are key drivers.

The market shows strong quality differentiation. Bulk fiber products are losing relevance. High-purity soluble concentrates are gaining preference. These products command 20% to 40% price premiums. Pharmaceutical-grade variants command even higher premiums.

• EFSA Health Claim Mandate: EU regulations support beta-glucan use for cholesterol reduction. Tate & Lyle PromOat qualifies under this claim. The CP Kelco acquisition strengthens its portfolio. [1]
• Asia Pacific Nutraceutical Growth: China and Japan are expanding functional food markets. Demand for cholesterol-lowering ingredients is increasing. Regulatory approvals are supporting adoption. [7]

U.S. FDA Labelling Update:  FDA updated its “healthy” definition in 2025. Beta-glucan products now qualify for premium positioning. This supports wider adoption in food categories.

Regional Analysis

The rye bran beta-glucan as cholesterol-lowering food ingredient market is assessed across Asia Pacific, Europe, North America, Latin America, and Middle East and Africa, covering 40+ countries with distinct demand profiles shaped by regulatory health claim frameworks, functional food sector maturity, ageing population dynamics, and cereal beta-glucan supply chain infrastructure. The full report provides market attractiveness analysis by region and country.

Source: Fact.MR (FACT.MR) analysis, based on proprietary forecasting model and primary research

Asia Pacific Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Analysis

Asia Pacific is the fastest-growing region. Growth is supported by regulatory expansion and rising health awareness. Demand reflects a mix of policy-driven and retail-led procurement. Kerry Group and DSM-Firmenich serve the region with diverse portfolios.

• China: Market in china is shaped by a strong e-commerce-led nutraceutical ecosystem. Growth is projected at 8.4% CAGR through 2036. Functional food brands are actively integrating beta-glucan into cholesterol-focused products. NHC approvals are enabling structured ingredient adoption. Demand remains regulatory-driven rather than retail-led.

• India: India’s growth is driven by expanding urban health awareness and dietary shifts. Demand is projected at 8.0% CAGR through 2036. Beta-glucan is being incorporated into bakery, dairy, and beverage products. FSSAI frameworks are supporting both domestic and imported supply. Growth is led by organised retail and supplement channels.
• Japan: Japan market is defined by strict clinical validation and premium positioning. Demand is projected at 7.2% CAGR through 2036. FOSHU and FFC systems are supporting continued product approvals. Procurement is highly specification-driven with strong focus on documented health claims.

FACT.MR covers China, India, Japan, South Korea, ASEAN, and Australia & New Zealand. Includes regulatory timelines, procurement benchmarks, and investment data.

Europe Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Analysis

Europe operates as a compliance-driven market with strict regulatory standards. EFSA health claims define adoption patterns across food categories. Kerry Group, Tate & Lyle, and Lantmännen maintain strong supply positions.

• Germany: Germany’s market benefits from its deep-rooted rye consumption and health-focused retail base. Growth is projected at 6.8% CAGR through 2036. EFSA-approved claims support strong on-pack positioning in functional foods. Tate & Lyle continues to expand supply capabilities through strategic acquisitions. Demand is structured and regulation-led.

FACT.MR covers Germany, France, the UK, Italy, Spain, Nordic countries, and BENELUX. Includes EFSA compliance data and procurement benchmarks.

North America Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Analysis

North America represents a mature and innovation-driven market. FDA-authorised health claims define ingredient positioning and competition. Kerry Group and Tate & Lyle hold strong positions through claim-backed portfolios.

• United States: The United States market is characterised by strong demand for functional and fortified foods. Growth is projected at 6.0% CAGR through 2036. FDA’s updated “healthy” labelling framework is expanding commercial opportunities. Beta-glucan is widely used in plant-based beverages and protein bars. Growth is moderated by competition from oat-based alternatives.

FACT.MR covers the United States, Canada, and Mexico. Includes FDA compliance data and functional food demand trends.

Competitive Aligners for Market Players

The rye bran beta-glucan as cholesterol-lowering food ingredient market is moderately concentrated, with a limited group of established suppliers controlling the majority of claim-eligible, high-purity beta-glucan supply. Key players such as Kerry Group, Tate & Lyle, DSM-Firmenich, and Lantmännen dominate premium functional food and supplement procurement. Competitive differentiation is driven primarily by regulatory compliance, health claim validation, and consistency of product specifications rather than pricing alone, particularly within EFSA and FDA-regulated markets.

Leading suppliers benefit from vertically integrated cereal processing capabilities and strong regulatory expertise. Tate & Lyle maintains a competitive edge through its PromOat beta-glucan, which holds both European Commission and FDA-authorised cholesterol health claims. Its acquisition of CP Kelco in 2024 has further expanded its specialty ingredient portfolio and global supply capabilities. Lantmännen focuses on oat-derived soluble beta-glucan, supported by documented extraction processes and application-level technical support for food and cosmetic manufacturers. Meanwhile, Lesaffre has strengthened its position through the acquisition of Biorigin, enhancing its yeast-derived beta-glucan portfolio for supplement applications. Procurement across functional food and nutraceutical manufacturers is highly specification-driven. Buyers require validated purity levels, viscosity profiles, and alignment with approved health claims before supplier onboarding.

Once a specific beta-glucan grade is incorporated into a formulation, switching costs are significant due to reformulation requirements and regulatory revalidation. This creates long-term supplier relationships and reinforces pricing power for compliant producers. Large supplement and food brands are increasingly adopting dual-sourcing strategies, particularly between Tate & Lyle and Kerry Group, to balance supply security with regulatory continuity.

Key Players

• Kerry Group
• DSM-Firmenich
• Kemin Industries
• Lantmännen
• Tate & Lyle
• Lesaffre

Bibliography

• [1] Lantmannen Functional Foods / European Commission. PromOat Oat Beta-Glucan European Commission Authorised Health Claim: 'Oat Beta-Glucan Has Been Shown to Lower/Reduce Blood Cholesterol' Under Regulation EC 1924/2006. lantmannenfunctionalfoods.com / knowde.com/stores/lantmannen-functional-foods
• [2] Tate & Lyle PLC. (November 2024). Completion of Combination of Tate & Lyle and CP Kelco to Create a Leading Global Speciality Food and Beverage Solutions Business. November 15, 2024. tateandlyle.com/news
• [3] Food Ingredient First. (October 2024). Lesaffre Acquires 70% Stake in Biorigin, Brazilian Yeast-Derived Products Specialist for Human and Animal Nutrition Including Beta-Glucan Derivatives. October 2024. foodingredientsfirst.com
• [4] Tate & Lyle PLC. FDA Healthy Food Labelling Update February 2025: PromOat Beta-Glucan Qualification Under FDA Updated 'Healthy' Food Labelling Definition Through Pre-Existing Authorised Oat Beta-Glucan Cholesterol-Lowering Health Claim at 3-Gram Daily Intake. tateandlyle.com/news
• [5] Mordor Intelligence / Layn Natural Ingredients. (February 2025). Layn Natural Ingredients Develops Galacan Soluble Beta-Glucan via Precision Fermentation at Expanded Biotechnology Facility: Improved Bioavailability and Water Solubility for Gut Health and Functional Food Applications. February 2025. mordorintelligence.com
• [6] Mordor Intelligence. (2024-2025). Soluble Beta-Glucan Market Analysis: EFSA Approval of Paramylon from Euglena gracilis as Novel Food Ingredient 2024; Food and Beverages 57.19% Revenue Share 2024; Dietary Supplements 8.06% CAGR. mordorintelligence.com/industry-reports/soluble-beta-glucan-market
• [7] NutraIngredients / Smooth Link Inc. (December 2025). Japan Immune Health Functional Foods Record High: 1,584 Foods with Function Claims Notified to CAA in FY2024 Surpassing Prior Year 1,433 Notifications. December 2025. nutraingredients.com

This Report Addresses

• Strategic insights on rye bran beta-glucan demand across China e-commerce nutraceutical expansion, India retail-led functional food adoption, Japan FOSHU-framework heart-health procurement, Germany EFSA clean-label reformulation, and U.S. FDA healthy labelling-driven ingredient upgrading.
• Market forecast from USD 0.7 billion in 2026 to USD 1.3 billion by 2036 at a CAGR of 6.0%.
• Growth opportunity mapping across soluble beta-glucan functional food fortification, cereal-source cholesterol claims compliance, dietary supplement channel expansion, and pharmaceutical-grade ingredient adoption.
• Segment analysis by source (yeast-derived, cereal-based), type (soluble, insoluble), and application (food & beverages, dietary supplements, pharmaceuticals).
• Regional outlook covering Asia Pacific nutraceutical-led demand growth, European EFSA-claim-driven functional food reformulation cycles, and North America FDA healthy labelling-led procurement expansion.
• Competitive landscape of Kerry Group, Tate & Lyle, DSM-Firmenich, Lantmännen, Kemin Industries, and Lesaffre. Focus on EFSA and FDA health claim dossier quality, purity standardisation, and application-specific grade documentation.
• Regulatory impact analysis covering EFSA Regulation EC 1924/2006 cholesterol health claim requirements, FDA authorised oat beta-glucan health claims, Japan FOSHU and FFC framework approvals, and FSSAI functional ingredient review pathways.
• Report delivered in PDF, Excel datasets, and presentation formats. Supported by primary research, regulatory filings, producer disclosures, and functional food procurement benchmarks.

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Definition

The market covers rye bran beta-glucan concentrates in soluble and insoluble forms. These are used as cholesterol-lowering functional ingredients. They are applied in bakery, beverages, supplements, and pharmaceuticals.

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Inclusions

Includes global and regional forecasts from 2026 to 2036 by source, type, and application. Covers cereal-based and yeast-derived beta-glucan. Includes food, supplement, and pharmaceutical applications.

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Exclusions

Excludes mushroom and seaweed-derived beta-glucans. Finished functional food and retail supplement products are not included. Focus remains on ingredient-level supply to processors.

Rye Bran Beta-Glucan as Cholesterol-Lowering Food Ingredient Market Research Methodology

• Primary Research: Includes interviews with ingredient suppliers, formulators, brand managers, and procurement specialists across key markets.
• Desk Research: Covers EFSA and FDA health claim data, FSSAI approvals, and Japan FOSHU database. Includes producer reports from 2024 to 2025.
• Market Sizing and Forecasting: Uses a hybrid top-down and bottom-up model. Based on production volumes, pricing, and application demand.
• Data Validation and Update Cycle: Validated through producer revenues, regulatory filings, and procurement benchmarks. Updated regularly.